• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer

    4/9/24 4:05:00 PM ET
    $ILMN
    $SMMT
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ILMN alert in real time by email

    Joydeep Goswami to serve as advisor through June 30

    Illumina reaffirms Q1 2024 and full-year 2024 financial guidance

    SAN DIEGO, April 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team appointments.

    Ankur Dhingra, who will become Illumina's Chief Financial Officer on April 15.

    Ankur Dhingra is joining Illumina as Chief Financial Officer (CFO), leading Illumina's financial planning and analysis, accounting, investor relations, internal audit, tax, and treasury functions. Dhingra brings a breadth of experience from the life sciences tools, diagnostics, and pharmaceutical industries. He formerly was CFO at Summit Therapeutics Inc. (NASDAQ:SMMT), and prior to that was CFO of CAREDx, Inc. Dhingra spent more than 18 years at Agilent Technologies, most recently as VP, Investor Relations. Before that, he held various finance leadership roles with progressively increasing responsibility, including multiple business unit CFO roles. He brings experience in developing and executing growth and margin improvement strategies, delivering P&L commitments, and driving businesses toward increasing levels of performance. Dhingra has a demonstrated record of success in executing and influencing growth-oriented business strategies, as well as managing global finance and accounting teams. He is a Chartered Accountant and member of The Institute of Chartered Accountants of India.

    Jakob Wedel has been named Chief Strategy and Corporate Development Officer. Wedel joined Illumina in November 2023 as CEO Chief of Staff, leading strategic transformation initiatives. In his new role, Wedel is responsible for driving Illumina's strategic planning, partnerships, and acquisitions. Previously, Wedel was partner at EY's strategy practice, co-leading their global life science practice, and served in roles at McKinsey & Company and Bain & Company. In the early 2000s, Wedel co-founded the Nordic strategy firm QVARTZ, which was later acquired by Bain.

    "I am proud of the talent joining our management team as we work to deliver on Illumina's mission to improve human health by unlocking the power of the genome," said Jacob Thaysen, Illumina CEO. "Ankur brings deep financial expertise, investor and leadership experience, and industry knowledge to Illumina's CFO role, and Jakob has keen insights gained from 25 years in strategy leadership roles with global consulting firms. Both are deeply committed to serving our customers and helping Illumina grow."

    Dhingra and Wedel are both relocating to San Diego. They succeed Goswami, who held both the CFO and Chief Strategy and Corporate Development Officer roles since early 2023. Goswami joined Illumina in 2019 to lead strategy and corporate development. He will continue as an advisor to the company starting April 15 and through June 30. He departs the organization on July 1.

    "We are grateful to Joydeep for his many contributions to Illumina over more than four years, and for most recently leading these two key functions," said Thaysen. "Joydeep will continue with us for several weeks to support a smooth leadership transition."

    The company has reaffirmed its guidance for the first quarter 2024 and full-year 2024, as announced during its fourth quarter 2023 earnings call on February 8, 2024.

    About Illumina

    Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

    Contacts

    Investors:

    Salli Schwartz

    858-291-6421

    [email protected]

    Media:

    David McAlpine

    347-327-1336

    [email protected]

    Jakob Wedel, who will become Illumina's Chief Strategy and Corporate Development Officer on April 15.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-appoints-ankur-dhingra-chief-financial-officer-jakob-wedel-chief-strategy-and-corporate-development-officer-302112206.html

    SOURCE Illumina, Inc.

    Get the next $ILMN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ILMN
    $SMMT

    CompanyDatePrice TargetRatingAnalyst
    Illumina Inc.
    $ILMN
    8/12/2025$94.00Outperform → Neutral
    Daiwa Securities
    Illumina Inc.
    $ILMN
    7/11/2025$125.00Sector Outperform → Sector Perform
    Scotiabank
    Summit Therapeutics Inc.
    $SMMT
    7/1/2025$30.00Buy
    UBS
    Summit Therapeutics Inc.
    $SMMT
    6/11/2025$12.00Underperform
    Leerink Partners
    Summit Therapeutics Inc.
    $SMMT
    3/26/2025$23.00 → $35.00Neutral → Buy
    Citigroup
    Summit Therapeutics Inc.
    $SMMT
    3/21/2025Overweight
    Cantor Fitzgerald
    Summit Therapeutics Inc.
    $SMMT
    3/12/2025$30.00Outperform
    Evercore ISI
    Illumina Inc.
    $ILMN
    3/4/2025$130.00 → $90.00Neutral
    Citigroup
    More analyst ratings

    $ILMN
    $SMMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Illumina downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Illumina from Outperform to Neutral and set a new price target of $94.00

    8/12/25 7:55:50 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina downgraded by Scotiabank with a new price target

    Scotiabank downgraded Illumina from Sector Outperform to Sector Perform and set a new price target of $125.00

    7/11/25 8:11:04 AM ET
    $ILMN
    Medical Specialities
    Health Care

    UBS initiated coverage on Summit Therapeutics with a new price target

    UBS initiated coverage of Summit Therapeutics with a rating of Buy and set a new price target of $30.00

    7/1/25 8:22:46 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ILMN
    $SMMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Chief Financial Officer Dhingra Ankur bought $495,381 worth of shares (6,100 units at $81.21), increasing direct ownership by 32% to 24,906 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    5/14/25 4:20:13 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Chief Executive Officer Thaysen Jacob bought $998,674 worth of shares (12,350 units at $80.86), increasing direct ownership by 17% to 83,390 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    5/14/25 4:18:28 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Zanganeh Mahkam bought $411,094 worth of shares (110,321 units at $3.73), increasing direct ownership by 5% to 520,814 units (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    3/27/24 8:28:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ILMN
    $SMMT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioStem Technologies Appoints Brandon Poe as Chief Financial Officer

    POMPANO BEACH, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. ("BioStem" or the "Company") (OTC:BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the appointment of Brandon Poe as its Chief Financial Officer (CFO). Mr. Poe has served on BioStem's Board of Directors since 2022. Michael Fortunato, the Company's prior CFO, has assumed the role of Chief Accounting Officer. "I'm excited to welcome Brandon as CFO during this pivotal period of growth and innovation for BioStem," said Jason Matuszewski, Chairman and CEO. "Brandon brings proven financial leader

    8/14/25 4:01:44 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

    Ivonescimab in Combination with Chemotherapy Showed Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Global Phase III HARMONi Trial Evaluating Patients with EGFRm NSCLC after EGFR TKI Therapy; Positive Trend Observed in Overall Survival Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China; Ivonescimab Monotherapy Approved by NMPA in China for 1L PD-L1 Positive Advanced NSCLC Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant, Clinically Mea

    8/11/25 5:03:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025

    Revenue of $1.06 billion for Q2 2025, down 3% from Q2 2024 on both a reported and constant currency basisGAAP operating margin of 20.2% and non-GAAP operating margin of 23.8% for Q2 2025GAAP diluted EPS of $1.49 and non-GAAP diluted EPS of $1.19 for Q2 2025Cash provided by operations of $234 million and free cash flow of $204 million for Q2 2025For fiscal year 2025, we now expect:Total company constant currency revenue decline in the range of (2.5%) to (0.5%), up from (3%) to (1%) previouslyNon-GAAP operating margin of approximately 22% - 22.5%, up from 21.5% - 22.0% previouslyNon-GAAP diluted EPS in the range of $4.45 - $4.55, an increase from our May guidance of $4.20 - $4.30. This include

    7/31/25 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    $SMMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Chief Commercial Officer Cunningham Everett covered exercise/tax liability with 4,248 shares, decreasing direct ownership by 9% to 41,942 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    7/8/25 5:59:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Director Ullem Scott B. was granted 307 shares, increasing direct ownership by 4% to 8,137 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    7/2/25 4:26:43 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Co-Chief Executive Officer Zanganeh Mahkam exercised 74,545 shares at a strike of $2.64 (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    6/2/25 5:01:16 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ILMN
    $SMMT
    Financials

    Live finance-specific insights

    View All

    Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

    Ivonescimab in Combination with Chemotherapy Showed Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Global Phase III HARMONi Trial Evaluating Patients with EGFRm NSCLC after EGFR TKI Therapy; Positive Trend Observed in Overall Survival Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China; Ivonescimab Monotherapy Approved by NMPA in China for 1L PD-L1 Positive Advanced NSCLC Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant, Clinically Mea

    8/11/25 5:03:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025

    Revenue of $1.06 billion for Q2 2025, down 3% from Q2 2024 on both a reported and constant currency basisGAAP operating margin of 20.2% and non-GAAP operating margin of 23.8% for Q2 2025GAAP diluted EPS of $1.49 and non-GAAP diluted EPS of $1.19 for Q2 2025Cash provided by operations of $234 million and free cash flow of $204 million for Q2 2025For fiscal year 2025, we now expect:Total company constant currency revenue decline in the range of (2.5%) to (0.5%), up from (3%) to (1%) previouslyNon-GAAP operating margin of approximately 22% - 22.5%, up from 21.5% - 22.0% previouslyNon-GAAP diluted EPS in the range of $4.45 - $4.55, an increase from our May guidance of $4.20 - $4.30. This include

    7/31/25 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025

    SAN DIEGO, July 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the second quarter 2025 following the close of market on Thursday, July 31, 2025. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, July 31, 2025. Interested parties may access the live webcast via the Investor Info section of Illumina's

    7/10/25 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    $SMMT
    Leadership Updates

    Live Leadership Updates

    View All

    BioStem Technologies Appoints Brandon Poe as Chief Financial Officer

    POMPANO BEACH, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. ("BioStem" or the "Company") (OTC:BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the appointment of Brandon Poe as its Chief Financial Officer (CFO). Mr. Poe has served on BioStem's Board of Directors since 2022. Michael Fortunato, the Company's prior CFO, has assumed the role of Chief Accounting Officer. "I'm excited to welcome Brandon as CFO during this pivotal period of growth and innovation for BioStem," said Jason Matuszewski, Chairman and CEO. "Brandon brings proven financial leader

    8/14/25 4:01:44 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors

    Stephen MacMillan to retire from the Board SAN DIEGO, March 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today announced changes to its Board of Directors. Scott Gottlieb, MD, has been elected non-executive Chair of Illumina's Board. Dr. Gottlieb has served on the Board of Directors since 2020. Additionally, Keith Meister, founder, Managing Partner, and Chief Investment Officer of Corvex Management, will join the Board of Directors on March 28, 2025. Stephen MacMillan, Chairman, President, and CEO of Hologic, who joined the Illumina Board in June 2023, has decided to retire from the board in preparation for the company

    3/25/25 9:00:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

    Mr. LaCaze Brings Over 35 Years of Executive Leadership Experience in the Biopharmaceutical Industry Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Robert LaCaze has joined Summit Therapeutics as Chief Commercial Officer, reporting to Manmeet S. Soni, Chief Operating Officer and Chief Financial Officer, effective immediately. Robert W. Duggan and Dr. Maky Zanganeh, Co-CEOs of Summit Therapeutics, stated, "Robert's extensive experience and proven track record in the oncology space make him an exceptional addition to our team. His leadership will be instrumental as we seek to bring ivonescimab to patients in need. We are truly excited to have

    3/17/25 4:24:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ILMN
    $SMMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    12/6/24 10:11:24 AM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Illumina Inc.

    SC 13G - ILLUMINA, INC. (0001110803) (Subject)

    12/5/24 7:27:01 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    11/12/24 3:59:44 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    $SMMT
    SEC Filings

    View All

    Summit Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Summit Therapeutics Inc. (0001599298) (Filer)

    8/11/25 5:13:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Summit Therapeutics Inc.

    8-K - Summit Therapeutics Inc. (0001599298) (Filer)

    8/11/25 4:51:33 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Summit Therapeutics Inc.

    424B5 - Summit Therapeutics Inc. (0001599298) (Filer)

    8/11/25 4:49:10 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care